drugset / Trial / NCT01154114
Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine any differences in pharmacokinetic parameters of darapladib when dosed to people with moderate liver disease as compared to when dosed in normal healthy volunteers.
Timeline
- Start
- 2010-07-01
- Primary completion
- 2010-10-15
- Completion
- 2010-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darapladib | Small molecule | 40 mg | Oral |